MetrioPharm Investor Relations News QIV 2018


Retrospect of the year by Dr. Wolfgang Brysch, CEO of MetrioPharm

Dear Shareholders
In 2018, we took a decisive step towards obtaining regulatory approval for MP1032: This year we started our large Phase II clinical trial. Of course I can't tell you about the results of the currently blinded study yet, but we do know: We have almost completed the recruitment of the patients and I would like to thank all our employees for their outstanding work on the study.

Preparations for further studies are already underway and we will keep you informed about all major developments in the coming year.

MetrioPharm also closed a financing round for CHF 20 million in 2018. I was very pleased to meet many of you personally (again) during the course of the year. And I have passed on your positive feedback on the progress of our work to the team - it is a strong incentive for us. Personally, I was delighted that many long-standing shareholders also participated in the new subscription round. We are very grateful for this continued vote of confidence.

I would now like to wish all MetrioPharm AG shareholders who have been with us for many years as well as all new shareholders a Merry Christmas and relaxing holidays.

Yours sincerely

Dr. Wolfgang Brysch

Chief Executive Officer

ECTRIMS Congress, Berlin, Germany

The Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) took place in Berlin in October. Dr. Astrid Kaiser, Head of Drug Development, and Dr. Sara Schumann, Project Manager Research and Development, attended the congress. They presented first, promising results from preclinical research on the indication multiple sclerosis for MetrioPharm.

BIO Investor Forum, San Francisco, USA

At the BIO Investor Forum, listed and established private companies from the healthcare sector present themselves. Dr. Wolfgang Brysch, CEO, and Eva Brysch, Head of Investor Relations, represented MetrioPharm AG. They took the opportunity to talk to potential investors as part of the one-on-one partnering.

German Equity Forum 2018, Frankfurt, Germany

MetrioPharm AG took part in the German Equity Forum for the third time this year. Dr. Wolfgang Brysch, CEO, and Eva Brysch, Head of Investor Relations, held a presentation and then used opportunities for one-on-one meetings to establish new contacts.

M.M. Warburg & Co Investor Conference - Meet-the-Future, Berlin, Germany

At the invitation of M.M. Warburg & Co, young companies presented their vision of the future at the exclusive Meet-the-Future conference in November. Companies from the fields of technology, finance and healthcare were attending. MetrioPharm was represented by Dr. Wolfgang Brysch, CEO, and Eva Brysch, Head of Investor Relations. Their vision of the future for MetrioPharm outlined at this forum received very positive feedback from participants and international investors.

MetrioPharm Blog: Ask the CEO

On the MetrioPharm Blog you will find Dr. Wolfgang Brysch's answer to the most frequently asked question of 2018. It is on the topic of InflammAging. Click here to go to the MetrioPharm Blog.


Corporate calendar of MetrioPharm AG in QI 2019

January 07-10, 2019: J.P. Morgan Healthcare Conference, San Francisco, USA
The J.P. Morgan Healthcare Conference has established itself as one of the leading conferences for the healthcare sector. On behalf of MetrioPharm AG, Dr. Wolfgang Brysch, CEO, Barry Frankel, Senior Vice President Strategy and Business Development, and Felix Edler, Business Development, will deepen discussions with potential cooperation and licensing partners. In addition, Eva Brysch, Head of Investor Relations, will speak with potential investors and partners from the financial world.

February 11-12, 2019: BIO CEO & Investor Conference, New York, USA
The BIO CEO & Investor Conference is one of the largest investor conferences focusing on established and emerging listed and selected private biotech companies. It provides a neutral forum where institutional investors, industry analysts and biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. Dr. Wolfgang Brysch, CEO, and Eva Brysch, Head of Investor Relations, will attend this year's conference for MetrioPharm for the first time.

February 25-26, 2019: 12th Annual European Life Sciences CEO Forum, Zurich, Switzerland
This global forum of the biopharmaceutical industry will address the key investment, partnership and alliance management challenges for 2019 in its conference program. The key players will share their insights in discussion forums covering both the macro picture as well as innovations in different therapeutic fields. Dr. Wolfgang Brysch, CEO, will speak at the forum for Autoimmune and Inflammatory Diseases where he will contribute his expertise in this field.

Should further dates be added for the next quarter, please visit our website at www.metriopharm.com for more information.

Your contact:


Eva Brysch
Head of Investor Relations & Corporate Communications
Tel.: +49-(0)30-3384-395-40
E-Mail: invest@metriopharm.com


MetrioPharm AG Newsletter Download PDF